PRCSG_network

The mission of the PRCSG is to conduct high quality clinical trials, of therapeutic agents, in children with rheumatic diseases.

[PRCSG_network @NetworkPrcsg]

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study - Brunner - Arthritis & Rheumatology - Wiley Online Library https://t.co/ZlV9d7VH6G

[PRCSG_network @NetworkPrcsg]

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial - Brunner - 2026 - Arthritis & Rheumatology - Wiley Online Library https://t.co/bAxlCQQxM5

[PRCSG_network @NetworkPrcsg]

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial - Brunner - Arthritis Care & Research - Wiley Online Library https://t.co/Uk49BrJLbL

[Arthritis Foundation @ArthritisFdn]

🎄 Lace up & save! The Jingle Bell Run is coming, and now’s your chance to join in for less. Use code FALL for $5 off registration — limited time only! 🏃‍♀️❄️

Run for fun. Run for a cause. 👉 https://t.co/IeNZS8JT6I

#JingleBellRun

[PRCSG_network @NetworkPrcsg]

"Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting" — Read it on @ResearchGate: https://t.co/LcjyiYFIVL

[PRCSG_network @NetworkPrcsg]

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges - Shishov - 2025 - Arthritis Care & Research - Wiley Online Library https://t.co/XAuQozEv2P

[PRCSG_network @NetworkPrcsg]

https://t.co/LvrJLmx7To

[PRCSG_network @NetworkPrcsg]

Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Pos… https://t.co/zIt57UUqb2

[PRCSG_network @NetworkPrcsg]

Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations… https://t.co/fclFjtCIQb

[PRCSG_network @NetworkPrcsg]

Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Ar… https://t.co/CnSivE3mpE

[PRCSG_network @NetworkPrcsg]

Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis https://t.co/4H6qg9cFHc

[PRCSG_network @NetworkPrcsg]

Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study https://t.co/bHRYqps3eQ

[PRCSG_network @NetworkPrcsg]

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients with Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐label, Phase 1 Trial - Brunner - Arthritis Care & Research - Wiley Online Library https://t.co/46tEzR1fo7

[PRCSG_network @NetworkPrcsg]

Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction - Eloseily - Arthritis Care & Research - Wiley Online Library https://t.co/V0ljJsTfbP

[PRCSG_network @NetworkPrcsg]

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study https://t.co/B9STYG2Fen

[PRCSG_network @NetworkPrcsg]

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthrit… https://t.co/i3Dkl05jp4

[PRCSG_network @NetworkPrcsg]

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary re… https://t.co/uo7NUXW1Ht

[PRCSG_network @NetworkPrcsg]

We invite you to join us for a late breaking poster presentation on Safety and Efficacy of tofacitinib with sJIA @ACRheum on November 18.

Poster L09: November 18, 2024, 10:30 AM – 12:30 PM, Poster Session C, (L01-L14) Late Breaking Posters

[PRCSG_network @NetworkPrcsg]

We invite you to join us for a poster presentation on PK of ustekinumab in Juvenile Psoriatic Arthritis @ACRheum on November 16.

Poster 0384: November 16, 2024, 10:30 AM – 12:30 PM, Poster Session A, Pediatric Rheumatology – Clinical Poster I

[PRCSG_network @NetworkPrcsg]

Dr. Ekemini Ogbu Named Chair of ACR Pediatric Rheumatology Committee https://t.co/vQpbSxJLj4